Skip to main content
Publications
Hiligsmann M, Dellaert BG, Dirksen CD, Watson V, Bours S, Goemaere S, Reginster JY, Roux C, McGowan B, Silke C, Whelan B, Diez-Perez A, Torres E, Papadakis G, Rizzoli R, Cooper C, Pearson G, Boonen A. Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment. Rheumatology (Oxford). 2017 Jul 1;56(7):1167-76. doi: 10.1093/rheumatology/kex071
Horndler C, Gallego R, Garcia-Albeniz X, Alonso-Espinaco V, Alonso V, Escudero P, Jimeno M, Ortego J, Codony-Servat J, Fernandez-Martos C, Calatrava A, Marín-Aguilera M, Munoz J, Castellví-Bel S, Castells A, Rubini M, Gascon P, Maurel J. Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study. Cancer Biol Ther. 2011 Jan 15;11(2):177-83.
Becker N, Fortuny J, Alvaro T, Nieters A, Maynadie M, Foretova L, Staines A, Brennan P, Boffetta P, Cocco PL, de Sanjose S. Medical history and risk of lymphoma: results of a European case-control study (EPILYMPH). J Cancer Res Clin Oncol. 2009 Aug;135(8):1099-107. doi: 10.1007/s00432-009-0551